Comparative Pharmacology
Head-to-head clinical analysis: ARMONAIR RESPICLICK versus PULMICORT FLEXHALER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARMONAIR RESPICLICK versus PULMICORT FLEXHALER.
ARMONAIR RESPICLICK vs PULMICORT FLEXHALER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Armonair Respiclick is a metered-dose inhaler containing beclomethasone dipropionate, a corticosteroid. It exerts anti-inflammatory effects by binding to glucocorticoid receptors, inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing inflammatory cell migration and cytokine release in the airways.
Budesonide is a corticosteroid with potent anti-inflammatory effects. It inhibits multiple inflammatory cell types and mediators such as cytokines, chemokines, and adhesion molecules, reducing airway hyperresponsiveness and inflammation.
Inhaled: 55 mcg to 113 mcg per actuation, 1 to 2 actuations twice daily. Maximum 2 actuations twice daily.
Inhalation: 1-2 inhalations (90-180 mcg) twice daily; maximum 720 mcg twice daily.
None Documented
None Documented
Terminal elimination half-life is approximately 26 hours (range 21-36 hours). This supports once-daily dosing for bronchodilation in COPD.
Terminal half-life: 2.0-3.5 hours (mean 2.5 h) in adults after inhalation. Clinically, duration of effect may persist beyond pharmacokinetic half-life due to receptor binding.
Renal: approximately 99% of an administered dose is excreted in urine, with 95% as conjugated metabolites and 2% as free arformoterol. Fecal: approximately 1%. Biliary: negligible.
Renal: ~60% as metabolites, fecal: ~40% as metabolites. Less than 10% unchanged in urine.
Category C
Category C
Inhaled Corticosteroid
Inhaled Corticosteroid